Abstract

FXYD1 is a key protein controlling ion channel transport. FXYD1 exerts its function by regulating Na+/K+-ATPase activity, mainly in brain and cardiac tissues. Alterations of the expression level of the FXYD1 protein cause diastolic dysfunction and arrhythmias in heart and decreased neuronal dendritic tree and spine formation in brain. Moreover, FXYD1, a target of MeCP2, plays a crucial role in the pathogenesis of the Rett syndrome, a neurodevelopmental disorder. Thus, the amount of FXYD1 must be strictly controlled in a tissue specific manner and, likely, during development. Epigenetic modifications, particularly DNA methylation, represent the major candidate mechanism that may regulate Fxyd1 expression. In the present study, we performed a comprehensive DNA methylation analysis and mRNA expression level measurement of the two Fxyd1 transcripts, Fxyd1a and Fxyd1b, in brain and heart tissues during mouse development. We found that DNA methylation at Fxyd1a increased during brain development and decreased during heart development along with coherent changes in mRNA expression levels. We also applied ultra-deep methylation analysis to detect cell to cell methylation differences and to identify possible distinct methylation profile (epialleles) distribution between heart and brain and in different developmental stages. Our data indicate that the expression of Fxyd1 transcript isoforms inversely correlates with DNA methylation in developing brain and cardiac tissues suggesting the existence of a temporal-specific epigenetic program. Moreover, we identified a clear remodeling of epiallele profiles which were distinctive for single developmental stage both in brain and heart tissues.

Details

Title
Epigenetic remodelling of Fxyd1 promoters in developing heart and brain tissues
Author
Cuomo Mariella 1 ; Florio Ermanno 2 ; Della Monica Rosa 1 ; Costabile Davide 3 ; Buonaiuto Michela 1 ; Teodolinda, Di Risi 4 ; De Riso Giulia 5 ; Sarnataro Antonella 5 ; Cocozza, Sergio 5 ; Visconti, Roberta 6 ; Chiariotti Lorenzo 7 

 University of Naples “Federico II”, Department of Molecular Medicine and Medical Biotechnology, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); CEINGE-Biotecnologie Avanzate, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
 University of California, San Diego UCSD, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 CEINGE-Biotecnologie Avanzate, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); University of Naples, “Federico II”, SEMM-European School of Molecular Medicine, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
 CEINGE-Biotecnologie Avanzate, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); University of Naples “Federico II”, Department of Public Health, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
 University of Naples “Federico II”, Department of Molecular Medicine and Medical Biotechnology, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
 CEINGE-Biotecnologie Avanzate, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); Italian National Council of Research, Institute of Experimental Endocrinology and Oncology, Naples, Italy (GRID:grid.5326.2) (ISNI:0000 0001 1940 4177) 
 University of Naples “Federico II”, Department of Molecular Medicine and Medical Biotechnology, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); CEINGE-Biotecnologie Avanzate, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); University of Naples, “Federico II”, SEMM-European School of Molecular Medicine, Naples, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2652418401
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.